World’s first Covid-19 study where people are infected with virus to begin in London February 17, 2021 World's first Covid-19 study, where people are injected with virus, begins in London
AstraZeneca gets vaccine boost as sales jump to nearly $26bn February 11, 2021 Product sales at AstraZeneca jumped 10 per cent in 2020, up to nearly $26bn, in a year that made the at pharmaceutical company a household name. Total revenue at the business stood at $2.6bn, up nine per cent from 2019. Globally, new medicines represented 52 per cent of total revenue for the year. AstraZeneca’s share [...]
David Beckham-backed cannabis firm on course to become LSE’s first CBD listing February 4, 2021 UK-based Cellular Goods is seeking a listing on the London Stock Exchange, which would make them the LSE’s first pure-play CBD business
Oxford University given £100m to launch fight against antibiotic resistance January 19, 2021 The University of Oxford has been given £100m for a new institute focusing on resistance to antibiotics, one of the largest donations in its history. The gift will help combat the global issue of antimicrobial resistance (AMR), which is one of the world’s greatest healthcare challenges. The funding has been delivered by chemicals giant INEOS [...]
First psychedelic healthcare fund launches in Britain December 18, 2020 Britain’s first investment fund dedicated solely to psychedelic healthcare launched this week, allowing investors to put money into mind altering drugs for medical use. The fund, launched by London-based venture capital firm Neo Kuma, has an investment thesis focused on clinically proven psychedelic medicines that it believes will hit the market in the next five [...]
The new drug habits October 21, 2005 Pharmaceutical companies are increasingly turning to biotechnology ventures to help them rescue their flagging profits. Investors are looking at biotechnology companies to reinvigorate a moribund drug industry in a way the big pharmaceutical giants have failed to do over the last two years. Observers say companies such as America’s Pfizer or Britain’s GlaxoSmithKline, known as [...]
Flu anti-virus causes 17% profit jump October 20, 2005 Roche, the maker of bird flu anti-viral Tamiflu, yesterday announced a third quarter revenue increase of 17 per cent thanks to a jump in sales of the drug. The Swiss firm said sales of Tamiflu had more than doubled to SFr279m (£123m) and the companies overall sales for the quarter ending September climbed to SFr8.8bn. [...]